buy stock in good hands sl 4.5 MedinCell S.A. is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal therapeutic dose for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. As of March 31, 2022, the company has a portfolio of 2 products in clinical development and 7 products in the formulation or preclinical phase. Its most advanced product, mdc-MRI for the treatment of schizophrenia, is currently awaiting market approval in the United States.